{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:02:33Z","timestamp":1792512153300,"version":"4.5.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pasireotide, a novel multireceptor-targeted somatostatin receptor ligand (SRL) is characterized by a higher affinity to somatostatin receptor type 5 than type 2, unlike first-generation SRLs. Because of the broader binding profile, pasireotide has been suggested to have a greater clinical efficacy in acromegaly than first-generation SRLs and to be efficacious in Cushing\u2019s disease. The consequence of this binding profile is the increased blood glucose level in some patients. This results from the inhibition of both insulin secretion and the incretin effect and only a modest suppression of glucagon. A monthly intramuscular formulation of long-acting release pasireotide has been approved for both acromegaly and Cushing\u2019s disease treatment. This review presents data on the efficacy and safety of pasireotide treatment mostly in patients with acromegaly and Cushing\u2019s disease. Moreover, other possible therapeutic applications of pasireotide are mentioned.<\/jats:p>","DOI":"10.1007\/s11154-022-09710-3","type":"journal-article","created":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T23:34:59Z","timestamp":1642980899000},"page":"601-620","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Pasireotide\u2014a novel somatostatin receptor ligand after 20\u00a0years of use"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2360-6596","authenticated-orcid":false,"given":"Marek","family":"Bolanowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Ka\u0142u\u017cny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142aw","family":"Witek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Jawiarczyk-Przyby\u0142owska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"key":"9710_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.179.4068.77","volume":"179","author":"P Brazeau","year":"1973","unstructured":"Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973;179:77\u20139. https:\/\/doi.org\/10.1126\/science.179.4068.77.","journal-title":"Science"},{"key":"9710_CR2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1210\/edrv-16-4-427","volume":"16","author":"T Reisine","year":"1995","unstructured":"Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev. 1995;16:427\u201342. https:\/\/doi.org\/10.1210\/edrv-16-4-427.","journal-title":"Endocr Rev"},{"key":"9710_CR3","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1056\/NEJM198312223092506","volume":"309","author":"S Reichlin","year":"1983","unstructured":"Reichlin S. Somatostatin. N Engl J Med. 1983;309:1556\u201363. https:\/\/doi.org\/10.1056\/NEJM198312223092506.","journal-title":"N Engl J Med"},{"key":"9710_CR4","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3390\/ijms21051682","volume":"21","author":"M Gomes-Porras","year":"2021","unstructured":"Gomes-Porras M, Cardenas-Salas J, Alvarez-Escola C. Somatostatin analogs in clinical practice: a review. Int J Mol Sci. 2021;21:1682. https:\/\/doi.org\/10.3390\/ijms21051682.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"9710_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.tem.2009.12.003","volume":"21","author":"A Ben Shlomo","year":"2010","unstructured":"Ben Shlomo A, Melmed S. Pituitary somatostatin receptor signaling. Trends Endocrinol Metab. 2010;21(3):123\u201333. https:\/\/doi.org\/10.1016\/j.tem.2009.12.003.","journal-title":"Trends Endocrinol Metab"},{"key":"9710_CR6","doi-asserted-by":"publisher","unstructured":"Gunther T, Tulipano G, Dournaud P, et al. Somatostatin receptors: structure, function, ligands, and new nomenclature. Pharm Rev. 2018;70:763\u2013835. https:\/\/doi.org\/10.1124\/pr.117.015388.","DOI":"10.1124\/pr.117.015388"},{"key":"9710_CR7","doi-asserted-by":"publisher","unstructured":"Reubi JC, Kvols L, Krenning E, et al. Distribution of somatostatin receptors in normal and tumor tissue. Metabolism. 1990;39(9)suppl.2:78\u201381. https:\/\/doi.org\/10.1016\/0026-0495(90)90217-z.","DOI":"10.1016\/0026-0495(90)90217-z"},{"issue":"5","key":"9710_CR8","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1530\/eje.0.1460707","volume":"146","author":"C Bruns","year":"2002","unstructured":"Bruns C, Lewis I, Briner U, et al. SOM230: a novel somatostatin peptidometic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146(5):707\u201316. https:\/\/doi.org\/10.1530\/eje.0.1460707.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"9710_CR9","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1210\/jc.2008-1919","volume":"94","author":"S Lesche","year":"1995","unstructured":"Lesche S, Lehmann D, Nagel F, et al. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab. 1995;94(2):654\u201361. https:\/\/doi.org\/10.1210\/jc.2008-1919.","journal-title":"J Clin Endocrinol Metab"},{"key":"9710_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1006\/frne.1999.0183","volume":"20","author":"YC Patel","year":"1999","unstructured":"Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157\u201398. https:\/\/doi.org\/10.1006\/frne.1999.0183.","journal-title":"Front Neuroendocrinol"},{"key":"9710_CR11","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/0024-3205(82)90087-x","volume":"31","author":"W Bauer","year":"1982","unstructured":"Bauer W, Briner U, Doepfner W, et al. SOM 201\u2013995: a very potent and selective octapeptide analog of somatostatin with prolonged action. Life Sci. 1982;31:1133\u201340. https:\/\/doi.org\/10.1016\/0024-3205(82)90087-x.","journal-title":"Life Sci"},{"issue":"25","key":"9710_CR12","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1056\/NEJM198512193132504","volume":"313","author":"SW Lamberts","year":"1985","unstructured":"Lamberts SW, Uitterlinden P, Verschoor L, et al. Long-term treatment of acromegaly with the somatostatin analogue SMS 201\u2013995. N Engl J Med. 1985;313(25):1576\u201380. https:\/\/doi.org\/10.1056\/NEJM198512193132504.","journal-title":"N Engl J Med"},{"issue":"1","key":"9710_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1210\/jcem.79.1.8027218","volume":"79","author":"I Morange","year":"1994","unstructured":"Morange I, De Boisvilliers F, Chanson P, et al. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab. 1994;79(1):145\u201351. https:\/\/doi.org\/10.1210\/jcem.79.1.8027218.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"9710_CR14","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","volume":"21","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkhoudarian G, Beckers A, et al. Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord. 2020;21(4):667\u201378. https:\/\/doi.org\/10.1007\/s11154-020-09588-z.","journal-title":"Rev Endocr Metab Disord"},{"key":"9710_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-020-01091-7","author":"M Fleseriu","year":"2020","unstructured":"Fleseriu M, Biller BMK, Freda PU, et al. A Pituitary Society update to acromegaly management guidelines. Pituitary. 2020. https:\/\/doi.org\/10.1007\/s11102-020-01091-7.","journal-title":"Pituitary"},{"key":"9710_CR16","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1210\/jcem.80.11.7593436","volume":"80","author":"PM Stewart","year":"1995","unstructured":"Stewart PM, Kane KF, Stewart SE, et al. Depot long-acting somatostatin analog (Sandostatin LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab. 1995;80:3267\u201372. https:\/\/doi.org\/10.1210\/jcem.80.11.7593436.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9710_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1210\/jcem.87.1.8153","volume":"87","author":"P Caron","year":"2020","unstructured":"Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab. 2020;87(1):99\u2013104. https:\/\/doi.org\/10.1210\/jcem.87.1.8153.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9710_CR18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11102-017-0791-0","volume":"20","author":"MR Gadelha","year":"2017","unstructured":"Gadelha MR, Wildemberg LE, Bronstein MD, et al. Somatostatin receptor ligands in the treatment of acromegaly. Pituitary. 2017;20(1):100\u20138. https:\/\/doi.org\/10.1007\/s11102-017-0791-0.","journal-title":"Pituitary"},{"issue":"3","key":"9710_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11102-015-0684-z","volume":"19","author":"A Colao","year":"2016","unstructured":"Colao A, Auriemma RS, Pivonello R, et al. Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary. 2016;19(3):235\u201347. https:\/\/doi.org\/10.1007\/s11102-015-0684-z.","journal-title":"Pituitary"},{"issue":"4","key":"9710_CR20","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1210\/jc.2013-3318","volume":"99","author":"PJ Caron","year":"2014","unstructured":"Caron PJ, Bevan JS, Petersenn S, et al. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab. 2014;99(4):1282\u201390. https:\/\/doi.org\/10.1210\/jc.2013-3318.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"9710_CR21","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1210\/jc.2014-4113","volume":"100","author":"S Melmed","year":"2015","unstructured":"Melmed S, Popovic V, Bidlingmaier M, et al. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J Clin Endocrinol Metab. 2015;100(4):1699\u2013708. https:\/\/doi.org\/10.1210\/jc.2014-4113.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"9710_CR22","doi-asserted-by":"publisher","first-page":"e3785","DOI":"10.1210\/clinem\/dgaa526","volume":"105","author":"SL Samson","year":"2020","unstructured":"Samson SL, Nachtigall LB, Fleseriu M, et al. Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide. J Clin Endocrinol Metab. 2020;105(10):e3785\u201397. https:\/\/doi.org\/10.1210\/clinem\/dgaa526.","journal-title":"J Clin Endocrinol Metab"},{"key":"9710_CR23","doi-asserted-by":"publisher","unstructured":"Labadzhyan A, Nachtigall LB, Fleseriu M, et al. Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results. Pituitary. 2021; Jun 25. https:\/\/doi.org\/10.1007\/s11102-021-01163-2.","DOI":"10.1007\/s11102-021-01163-2"},{"issue":"10","key":"9710_CR24","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1210\/jc.2013-2262","volume":"98","author":"C Chieffo","year":"2013","unstructured":"Chieffo C, Cook D, Xiang Q, et al. Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly. J Clin Endocrinol Metab. 2013;98(10):4047\u201354. https:\/\/doi.org\/10.1210\/jc.2013-2262.","journal-title":"J Clin Endocrinol Metab"},{"key":"9710_CR25","doi-asserted-by":"publisher","unstructured":"Schmid HA. Pasireotide (SOM230): Development, mechanism of action and potential applications. Mol Cell Endocrinol. 2008;286:69\u201374. https:\/\/doi.org\/10.1016\/j.mce.2007.09.006.","DOI":"10.1016\/j.mce.2007.09.006"},{"issue":"3","key":"9710_CR26","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1210\/jc.2013-2480","volume":"99","author":"A Colao","year":"2014","unstructured":"Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014;99(3):791\u20139. https:\/\/doi.org\/10.1210\/jc.2013-2480.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"9710_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2213-8587(17)30326-1","volume":"6","author":"A Lacroix","year":"2018","unstructured":"Lacroix A, Gu F, Gallardo W, et al. Efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: a 12 months clinical trial. Lancet Diabetes Endocrinol. 2018;6(1):17\u201326. https:\/\/doi.org\/10.1016\/S2213-8587(17)30326-1.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"9710_CR28","doi-asserted-by":"publisher","unstructured":"Samson SL, Gu F, Feldt-Rasmussen U, et al. Managing pasireotide-associated hyperglycemia: a randomized, open-label, phase IV study. Pituitary. 2021; Jul 18. https:\/\/doi.org\/10.1007\/s11102-021-01161-4.","DOI":"10.1007\/s11102-021-01161-4"},{"key":"9710_CR29","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3389\/fendo.2018.00358","volume":"9","author":"F Ferra\u00f9","year":"2018","unstructured":"Ferra\u00f9 F, Albani A, Ciresi A, et al. Diabetes secondary to acromegaly: physiopathology, clinical features and effects of treatment. Front Endocrinol (Lausanne). 2018;9:358. https:\/\/doi.org\/10.3389\/fendo.2018.00358.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"9710_CR30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s11102-014-0585-6","volume":"18","author":"M Sheppard","year":"2015","unstructured":"Sheppard M, Bronstein MD, Freda P, et al. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of randomized, double-blind, multicenter, phase III study. Pituitary. 2015;18(3):385\u201394. https:\/\/doi.org\/10.1007\/s11102-014-0585-6.","journal-title":"Pituitary"},{"issue":"8","key":"9710_CR31","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1210\/jc.2013-1771","volume":"98","author":"RR Henry","year":"2013","unstructured":"Henry RR, Ciaraldi TP, Armstrong D, et al. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013;98(8):3446\u201353. https:\/\/doi.org\/10.1210\/jc.2013-1771.","journal-title":"J Clin Endocrinol Metab"},{"key":"9710_CR32","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3389\/fendo.2020.00028","volume":"11","author":"S Puglisi","year":"2020","unstructured":"Puglisi S, Ferra\u00f9 F, Ragonese M, et al. Cardiometabolic risk in acromegaly: A review with a focus on pasireotide. Front Endocrinol (Lausanne). 2020;11:28. https:\/\/doi.org\/10.3389\/fendo.2020.00028.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"9710_CR33","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"Melmed S, Bronstein MD, Chanson P, et al. A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14:552\u201361. https:\/\/doi.org\/10.1038\/s41574-018-0058-5.","journal-title":"Nat Rev Endocrinol"},{"key":"9710_CR34","doi-asserted-by":"publisher","unstructured":"Gadelha M, Colao A, Bex M, et al. Long-acting pasireotide provides clinical benefit to patients with uncontrolled acromegaly over continued treatment with first-generation somatostatin analogues (SSAs): Results from phase 3b, open-label study. Poster SAT-433. J Endocrine Soc. 2019;3:SAT-433. https:\/\/doi.org\/10.1210\/js.2019-SAT-433.","DOI":"10.1210\/js.2019-SAT-433"},{"key":"9710_CR35","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1210\/jc.2018-01979","volume":"104","author":"EC Coopmans","year":"2019","unstructured":"Coopmans EC, Muhammad A, van der Lely AJ, et al. How to position pasireotide LAR treatment in acromegaly. J Clin Endocrinol Metab. 2019;104:1978\u201388. https:\/\/doi.org\/10.1210\/jc.2018-01979.","journal-title":"J Clin Endocrinol Metab"},{"key":"9710_CR36","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1530\/ERC-15-0478","volume":"23","author":"AF Daly","year":"2016","unstructured":"Daly AF, Lysy PA, Desfilles C, et al. GHRH excess and blockade in X-LAG syndrome. Endocr Relat Cancer. 2016;23:161\u201370. https:\/\/doi.org\/10.1530\/ERC-15-0478.","journal-title":"Endocr Relat Cancer"},{"key":"9710_CR37","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1210\/jc.2003-031052","volume":"89","author":"J van der Hoek","year":"2004","unstructured":"van der Hoek J, de Herder WW, Feelders RA, et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab. 2004;89:638\u201345. https:\/\/doi.org\/10.1210\/jc.2003-031052.","journal-title":"J Clin Endocrinol Metab"},{"key":"9710_CR38","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1210\/jc.2009-2272","volume":"95","author":"S Petersenn","year":"2010","unstructured":"Petersenn S, Schopohl J, Barkan A, et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab. 2010;95:2781\u20139. https:\/\/doi.org\/10.1210\/jc.2009-2272.","journal-title":"J Clin Endocrinol Metab"},{"key":"9710_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12902-016-0096-8","volume":"16","author":"MD Bronstein","year":"2016","unstructured":"Bronstein MD, Fleseriu M, Neggers S, et al. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, phase III study. BMC Endocr Disord. 2016;16:16. https:\/\/doi.org\/10.1186\/s12902-016-0096-8.","journal-title":"BMC Endocr Disord"},{"key":"9710_CR40","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1210\/jc.2017-00135","volume":"102","author":"F Gatto","year":"2017","unstructured":"Gatto F, Feelders RA, Franck SE, et al. In vitro head-to-head comparison between octreotide and pasireotide in GH-secreting pituitary adenomas. J Clin Endocrinol Metab. 2017;102:2009\u201318. https:\/\/doi.org\/10.1210\/jc.2017-00135.","journal-title":"J Clin Endocrinol Metab"},{"key":"9710_CR41","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1530\/JOE-16-0332","volume":"231","author":"A Ib\u00e1\u00f1ez-Costa","year":"2016","unstructured":"Ib\u00e1\u00f1ez-Costa A, Rivero-Cort\u00e9s E, V\u00e1zquez-Borrego MC, et al. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro. J Endocrinol. 2016;231:135\u201345. https:\/\/doi.org\/10.1530\/JOE-16-0332.","journal-title":"J Endocrinol"},{"key":"9710_CR42","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","volume":"2","author":"MR Gadelha","year":"2014","unstructured":"Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2:875\u201384. https:\/\/doi.org\/10.1016\/S2213-8587(14)70169-X.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"9710_CR43","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1530\/EJE-19-0762","volume":"182","author":"A Colao","year":"2020","unstructured":"Colao A, Bronstein MD, Brue T, et al. Pasireotide for acromegaly: long-term outcomes from an extension to the phase III PAOLA study. Eur J Endocrinol. 2020;182:583. https:\/\/doi.org\/10.1530\/EJE-19-0762.","journal-title":"Eur J Endocrinol"},{"key":"9710_CR44","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1210\/jc.2017-02017","volume":"103","author":"A Muhammad","year":"2018","unstructured":"Muhammad A, van der Lely AJ, Delhanty PJD, et al. Efficacy and safety of switching to pasireotide in patients with acromegaly controlled with pegvisomant and first-generation somatostatin analogues (PAPE study). J Clin Endocrinol Metab. 2018;103:586\u201395. https:\/\/doi.org\/10.1210\/jc.2017-02017.","journal-title":"J Clin Endocrinol Metab"},{"key":"9710_CR45","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1530\/EJE-18-0353","volume":"179","author":"A Muhammad","year":"2018","unstructured":"Muhammad A, Coopmans EC, Delhanty PJD, et al. Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study. Eur J Endocrinol. 2018;179:269\u201377. https:\/\/doi.org\/10.1530\/EJE-18-0353.","journal-title":"Eur J Endocrinol"},{"key":"9710_CR46","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s12020-018-1690-5","volume":"62","author":"I Shimon","year":"2018","unstructured":"Shimon I, Adnan Z, Gorshtein A, et al. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study. Endocrine. 2018;62:448\u201355. https:\/\/doi.org\/10.1007\/s12020-018-1690-5.","journal-title":"Endocrine"},{"key":"9710_CR47","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1530\/EC-19-0332","volume":"8","author":"H Lasolle","year":"2019","unstructured":"Lasolle H, Ferriere A, Vasiljevic A, et al. Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study. Endocr Connect. 2019;8:1383\u201394. https:\/\/doi.org\/10.1530\/EC-19-0332.","journal-title":"Endocr Connect"},{"key":"9710_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.633944","volume":"12","author":"P Witek","year":"2021","unstructured":"Witek P, Bolanowski M, Szamotulska K, et al. The effect of 6 months\u2019 treatment with pasireotide LAR on glucose metabolism in patients with resistant acromegaly in real-world clinical settings. Front Endocrinol (Lausanne). 2021;12: 633944. https:\/\/doi.org\/10.3389\/fendo.2021.633944.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"9710_CR49","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S2213-8587(19)30113-5","volume":"7","author":"EC Coopmans","year":"2019","unstructured":"Coopmans EC, van der Lely A, Schneiders JJ, et al. Potential antitumour activity of pasireotide on pituitary tumours in acromegaly. Lancet Diabetes Endocrinol. 2019;7:425\u20136. https:\/\/doi.org\/10.1016\/S2213-8587(19)30113-5.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"9710_CR50","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1530\/EJE-19-0840","volume":"182","author":"EC Coopmans","year":"2020","unstructured":"Coopmans EC, Schneiders JJ, El-Sayed N, et al. T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly. Eur J Endocrinol. 2020;182:595\u2013605. https:\/\/doi.org\/10.1530\/EJE-19-0840.","journal-title":"Eur J Endocrinol"},{"key":"9710_CR51","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1530\/EJE-15-0832","volume":"174","author":"D Iacovazzo","year":"2016","unstructured":"Iacovazzo D, Carlsen E, Lugli F, et al. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol. 2016;174:241\u201350. https:\/\/doi.org\/10.1530\/EJE-15-0832.","journal-title":"Eur J Endocrinol"},{"key":"9710_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.648411","volume":"12","author":"M Puig-Domingo","year":"2021","unstructured":"Puig-Domingo M, Bernab\u00e9u I, Pic\u00f3 A, et al. Pasireotide in the personalized treatment of acromegaly. Front Endocrinol (Lausanne). 2021;12: 648411. https:\/\/doi.org\/10.3389\/fendo.2021.648411.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"9710_CR53","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1530\/EJE-20-0767","volume":"184","author":"S Chiloiro","year":"2021","unstructured":"Chiloiro S, Giampietro A, Mirra F, et al. Pegvisomant and pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. Eur J Endocrinol. 2021;184:217\u201329. https:\/\/doi.org\/10.1530\/EJE-20-0767.","journal-title":"Eur J Endocrinol"},{"key":"9710_CR54","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1046\/j.1365-2265.2000.00986.x","volume":"52","author":"S Kasayama","year":"2000","unstructured":"Kasayama S, Otsuki M, Takagi M, et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf). 2000;52:549\u201355. https:\/\/doi.org\/10.1046\/j.1365-2265.2000.00986.x.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"9710_CR55","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s11102-016-0734-1","volume":"19","author":"JM Silverstein","year":"2016","unstructured":"Silverstein JM. Hyperglycemia induced by pasireotide in patients with Cushing\u2019s disease or acromegaly. Pituitary. 2016;19:536\u201343. https:\/\/doi.org\/10.1007\/s11102-016-0734-1.","journal-title":"Pituitary"},{"key":"9710_CR56","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1530\/EC-20-0361","volume":"9","author":"MR Gadelha","year":"2020","unstructured":"Gadelha MR, Gu F, Bronstein MD, et al. Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. Endocr Connect. 2020;9:1178\u201390. https:\/\/doi.org\/10.1530\/EC-20-0361.","journal-title":"Endocr Connect"},{"key":"9710_CR57","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s12020-016-1182-4","volume":"55","author":"M Fleseriu","year":"2017","unstructured":"Fleseriu M, Rusch E, Geer EB, et al. Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study. Endocrine. 2017;55:247\u201355. https:\/\/doi.org\/10.1007\/s12020-016-1182-4.","journal-title":"Endocrine"},{"key":"9710_CR58","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N Engl J Med. 2012;366:914\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1105743.","journal-title":"N Engl J Med"},{"key":"9710_CR59","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s11102-013-0483-3","volume":"17","author":"A Colao","year":"2014","unstructured":"Colao A, De Block C, Gaztambide MS, et al. Managing hyperglycemia in patients with Cushing\u2019s disease treated with pasireotide: medical expert recommendations. Pituitary. 2014;17:180\u20136. https:\/\/doi.org\/10.1007\/s11102-013-0483-3.","journal-title":"Pituitary"},{"key":"9710_CR60","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.2174\/1871530320666200129113328","volume":"20","author":"R Cozzi","year":"2020","unstructured":"Cozzi R, Ambrosio MR, Attanasio R, et al. Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - part 2: Therapeutic issues. Endocr Metab Immune Disord Drug Targets. 2020;20:1144\u201355. https:\/\/doi.org\/10.2174\/1871530320666200129113328.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"9710_CR61","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s11102-013-0478-0","volume":"17","author":"S Petersenn","year":"2014","unstructured":"Petersenn S, Farrall AJ, De Block C, et al. Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, phase II extension study. Pituitary. 2014;17:132\u201340. https:\/\/doi.org\/10.1007\/s11102-013-0478-0.","journal-title":"Pituitary"},{"key":"9710_CR62","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1007\/BF03346419","volume":"31","author":"R Attanasio","year":"2008","unstructured":"Attanasio R, Mainolfi A, Grimaldi F, et al. Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients. J Endocrinol Invest. 2008;31:704\u201310. https:\/\/doi.org\/10.1007\/BF03346419.","journal-title":"J Endocrinol Invest"},{"key":"9710_CR63","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1210\/er.2013-1048","volume":"36","author":"R Pivonello","year":"2015","unstructured":"Pivonello R, De Leo M, Cozzolino A, et al. The treatment of Cushing disease. Endocr Rev. 2015;36:385\u2013486. https:\/\/doi.org\/10.1210\/er.2013-1048.","journal-title":"Endocr Rev"},{"key":"9710_CR64","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11102-018-0926-y","volume":"22","author":"F Gatto","year":"2019","unstructured":"Gatto F, Arvigo M, Amaru J. Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells. Pituitary. 2019;22:89\u201399. https:\/\/doi.org\/10.1007\/s11102-018-0926-y.","journal-title":"Pituitary"},{"issue":"suppl 1","key":"9710_CR65","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000314296","volume":"92","author":"LJ Hofland","year":"2010","unstructured":"Hofland LJ, Lamberts SWJ, Feelders R. Role of somatostatin receptors in normal and tumoral corticotroph cells. Neuroendocrinology. 2010;92(suppl 1):11\u20136. https:\/\/doi.org\/10.1159\/000314296.","journal-title":"Neuroendocrinology"},{"key":"9710_CR66","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/s11102-014-0618-1","volume":"18","author":"J Schopohl","year":"2015","unstructured":"Schopohl J, Gu F, Rubens R, et al. Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing`s disease: results from an open-ended, open-label extension trial. Pituitary. 2015;18:604\u201312. https:\/\/doi.org\/10.1007\/s11102-014-0618-1.","journal-title":"Pituitary"},{"key":"9710_CR67","doi-asserted-by":"publisher","unstructured":"Petersenn S, Salgado LR, Schopohl J, et al. Long-term treatment of Cushing`s disease with pasireotide. 5-year results from an open label extension study of a phase III trial. Endocrine. 2017;57:156\u201365. https:\/\/doi.org\/10.1007\/s12020-017-1316-3.","DOI":"10.1007\/s12020-017-1316-3"},{"key":"9710_CR68","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/cen.12431","volume":"81","author":"R Pivonello","year":"2014","unstructured":"Pivonello R, Petersenn S, Newell-Price J, et al. Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing`s disease: results from a phase III study. Clin Endocrinol (Oxf). 2014;81:408\u201317. https:\/\/doi.org\/10.1111\/cen.12431.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"9710_CR69","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s12020-018-1524-5","volume":"61","author":"A Albani","year":"2018","unstructured":"Albani A, Ferra\u00f9 F, Ciresi A, et al. Pasireotide treatment reduces cardiometabolic risk in Cushing\u2019s disease patients: an Italian, multicenter study. Endocrine. 2018;61:118\u201324. https:\/\/doi.org\/10.1007\/s12020-018-1524-5.","journal-title":"Endocrine"},{"key":"9710_CR70","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s12020-018-1818-7","volume":"64","author":"R Pivonello","year":"2019","unstructured":"Pivonello R, Arnaldi G, Scaroni A, et al. The medical treatment with pasireotide in Cushing`s disease: an Italian multicentre experience based on real-world evidence. Endocrine. 2019;64:657\u201372. https:\/\/doi.org\/10.1007\/s12020-018-1818-7.","journal-title":"Endocrine"},{"key":"9710_CR71","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s12020-015-0557-2","volume":"50","author":"C Simeoli","year":"2015","unstructured":"Simeoli C, Auriemma RS, Tortora F, et al. The treatment with pasireotide in Cushing`s disease: effects of long-term treatment on tumor mass in the experience of a single center. Endocrine. 2015;50:725\u201340. https:\/\/doi.org\/10.1007\/s12020-015-0557-2.","journal-title":"Endocrine"},{"key":"9710_CR72","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s11102-017-0853-3","volume":"21","author":"E Daniel","year":"2018","unstructured":"Daniel E, Debono M, Caunt S, et al. A prospective longitudinal study of pasireotide in Nelson`s syndrome. Pituitary. 2018;21:247\u201355. https:\/\/doi.org\/10.1007\/s11102-017-0853-3.","journal-title":"Pituitary"},{"key":"9710_CR73","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1677\/ERC-06-0026","volume":"14","author":"MC Zatelli","year":"2007","unstructured":"Zatelli MC, Piccin D, Vignali C, et al. Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr Rel Canc. 2007;14:91\u2013102. https:\/\/doi.org\/10.1677\/ERC-06-0026.","journal-title":"Endocr Rel Canc"},{"key":"9710_CR74","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/ng.3166","volume":"47","author":"M Reincke","year":"2015","unstructured":"Reincke M, Sbiera S, Hayakawa A, et al. Mutations in the deubiquitinase gene USP8 cause Cushing\u2019s disease. Nat Genet. 2015;47:31\u20138. https:\/\/doi.org\/10.1038\/ng.3166.","journal-title":"Nat Genet"},{"key":"9710_CR75","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/cr.2015.20","volume":"25","author":"ZY Ma","year":"2015","unstructured":"Ma ZY, Song ZJ, Chen JH, et al. Recurrent gain-of-function USP8 mutations in Cushing\u2019s disease. Cell Res. 2015;25:306\u201317. https:\/\/doi.org\/10.1038\/cr.2015.20.","journal-title":"Cell Res"},{"key":"9710_CR76","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s11102-019-01021-2","volume":"23","author":"A Lacroix","year":"2020","unstructured":"Lacroix A, Gu F, Schopohl J, et al. Pasireotide treatment significantly reduces tumor volume in patients with Cushing\u2019s disease: results from a phase 3 study. Pituitary. 2020;23:203\u201311. https:\/\/doi.org\/10.1007\/s11102-019-01021-2.","journal-title":"Pituitary"},{"issue":"2","key":"9710_CR77","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1530\/EJE-15-0689","volume":"174","author":"K Hayashi","year":"2016","unstructured":"Hayashi K, Inoshita N, Kawaguchi K, et al. The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing\u2019s disease. Eur J Endocrinol. 2016;174(2):213\u201326. https:\/\/doi.org\/10.1530\/EJE-15-0689.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"9710_CR78","doi-asserted-by":"publisher","first-page":"357","DOI":"10.5114\/fn.2020.102438","volume":"58","author":"P Witek","year":"2020","unstructured":"Witek P, Maksymowicz M, Szamotulska K, et al. MGMT expression in pituitary corticotroph adenomas and its relationship to clinical, pathological, and ultrastructural parameters in patients with Cushing\u2019s disease. Folia Neuropathol. 2020;58(4):357\u201364. https:\/\/doi.org\/10.5114\/fn.2020.102438.","journal-title":"Folia Neuropathol"},{"key":"9710_CR79","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1530\/EJE-13-0754","volume":"170","author":"C Giordano","year":"2014","unstructured":"Giordano C, Guarnotta V, Pivonello R, et al. Is diabetes in Cushing`s syndrome only a consequence of hypercortisolism? Eur J Endocrinol. 2014;170:311\u20139. https:\/\/doi.org\/10.1530\/EJE-13-0754.","journal-title":"Eur J Endocrinol"},{"key":"9710_CR80","unstructured":"Witek P, Zieli\u0144ski G, Szamotulska K, et al. Complications of Cushing`s disease \u2013 prospective evaluation and clinical characteristics. Do they affect the efficacy of surgical treatment? Endokrynol Pol. 2012;63:277\u2013285."},{"key":"9710_CR81","doi-asserted-by":"publisher","unstructured":"American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes - 2021. Diabetes Care. 2021;44(Suppl. 1):S15-S33. https:\/\/doi.org\/10.2337\/dc21-S002.","DOI":"10.2337\/dc21-S002"},{"key":"9710_CR82","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3389\/fendo.2020.00648","volume":"11","author":"R Pivonello","year":"2020","unstructured":"Pivonello R, Ferrigno R, De Martino MC, et al. Medical treatment of Cushing`s disease: an overview of the current and recent clinical trials. Front Endocrinol (Lausanne). 2020;11:648. https:\/\/doi.org\/10.3389\/fendo.2020.00648.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"9710_CR83","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1530\/EJE-19-0695","volume":"182","author":"J Newell-Price","year":"2020","unstructured":"Newell-Price J, Pivonello R, Tabarin A, et al. Use of late-night salivary cortisol to monitor response to medical treatment in Cushing\u2019s disease. Eur J Endocrinol. 2020;182:207\u201317. https:\/\/doi.org\/10.1530\/EJE-19-0695.","journal-title":"Eur J Endocrinol"},{"key":"9710_CR84","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S2213-8587(17)30341-8","volume":"6","author":"A Grossman","year":"2018","unstructured":"Grossman A. Is the new treatment for Cushing\u2019s disease too sweet? Lancet Diabetes Endocrinol. 2018;6:2\u20133. https:\/\/doi.org\/10.1016\/S2213-8587(17)30341-8.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"9710_CR85","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1056\/NEJMc1000094","volume":"362","author":"RA Feelders","year":"2010","unstructured":"Feelders RA, de Bruin C, Pereira AM, et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing\u2019s disease. N Engl J Med. 2010;362:1846\u20138. https:\/\/doi.org\/10.1056\/NEJMc1000094.","journal-title":"N Engl J Med"},{"key":"9710_CR86","unstructured":"Feelders RA, Kadioglu P, Bex M, et al. Prospective phase II study (CAPACITY) of pasireotide monotherapy or in combination with cabergoline in patients with Cushing\u2019s disease. Poster Presented at ENDO. Orlando, FL (2017)."},{"key":"9710_CR87","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, \u0106wik\u0142a JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1316158.","journal-title":"N Engl J Med"},{"key":"9710_CR88","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, M\u00fcller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656\u201363. https:\/\/doi.org\/10.1200\/JCO.2009.22.8510.","journal-title":"J Clin Oncol"},{"key":"9710_CR89","doi-asserted-by":"publisher","first-page":"5075","DOI":"10.2147\/DDDT.S84177","volume":"9","author":"EM Wolin","year":"2015","unstructured":"Wolin EM, Jarzab B, Eriksson B, et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther. 2015;9:5075\u201386. https:\/\/doi.org\/10.2147\/DDDT.S84177.","journal-title":"Drug Des Devel Ther"},{"key":"9710_CR90","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1530\/ERC-11-0367","volume":"19","author":"LK Kvols","year":"2012","unstructured":"Kvols LK, Oberg KE, O\u2019Dorisio TM, et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer. 2012;19:657\u201366. https:\/\/doi.org\/10.1530\/ERC-11-0367.","journal-title":"Endocr Relat Cancer"},{"key":"9710_CR91","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s12020-020-02406-1","volume":"70","author":"F Sileo","year":"2020","unstructured":"Sileo F, Cangiano B, Cacciatore C, et al. Off-label pasireotide treatment in one insulinoma patient with an atypical presentation and intolerant to diazoxide. Endocrine. 2020;70:435\u20138. https:\/\/doi.org\/10.1007\/s12020-020-02406-1.","journal-title":"Endocrine"},{"key":"9710_CR92","doi-asserted-by":"publisher","unstructured":"Siddiqui M, Vora A, Ali S, et al. Pasireotide: A novel treatment for tumor-induced hypoglycemia due to insulinoma and non-islet cell tumor hypoglycemia. J Endocr Soc. 2020;5:bvaa171. https:\/\/doi.org\/10.1210\/jendso\/bvaa171.","DOI":"10.1210\/jendso\/bvaa171"},{"key":"9710_CR93","doi-asserted-by":"publisher","unstructured":"Tirosh A, Stemmer SM, Solomonov E, et al. Pasireotide for malignant insulinoma. Hormones. 2016;15:271\u2013276. https:\/\/doi.org\/10.14310\/horm.2002.1639.","DOI":"10.14310\/horm.2002.1639"},{"key":"9710_CR94","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/cen.13503","volume":"88","author":"NS Hendren","year":"2018","unstructured":"Hendren NS, Panach K, Brown TJ, et al. Pasireotide for the treatment of refractory hypoglycaemia from malignant insulinoma. Clin Endocrinol. 2018;88:341\u20133. https:\/\/doi.org\/10.1111\/cen.13503.","journal-title":"Clin Endocrinol"},{"key":"9710_CR95","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s12020-018-1583-7","volume":"62","author":"A Faggiano","year":"2018","unstructured":"Faggiano A, Modica R, Severino R, et al. The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study. Endocrine. 2018;62:46\u201356. https:\/\/doi.org\/10.1007\/s12020-018-1583-7.","journal-title":"Endocrine"},{"key":"9710_CR96","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/JHC.S153672","volume":"5","author":"LG Feun","year":"2018","unstructured":"Feun LG, Wangpaichitr M, Li YY, et al. Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma. J Hepatocell Carcinoma. 2018;5:9\u201315. https:\/\/doi.org\/10.2147\/JHC.S153672.","journal-title":"J Hepatocell Carcinoma"},{"key":"9710_CR97","doi-asserted-by":"publisher","first-page":"935.e17","DOI":"10.1016\/j.urolonc.2020.07.005","volume":"38","author":"M Maas","year":"2020","unstructured":"Maas M, Mayer L, Hennenlotter J, et al. Prognostic impact of somatostatin receptor expression in advanced bladder cancer. Urol Oncol. 2020;38:935.e17-935.e28. https:\/\/doi.org\/10.1016\/j.urolonc.2020.07.005.","journal-title":"Urol Oncol"},{"key":"9710_CR98","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1210\/jcem.80.9.7673428","volume":"80","author":"JC Reubi","year":"1995","unstructured":"Reubi JC, Waser B, Schaer JC, et al. Somatostatin receptors in human prostate and prostate cancer. J Clin Endocrinol Metab. 1995;80:2806\u201314. https:\/\/doi.org\/10.1210\/jcem.80.9.7673428.","journal-title":"J Clin Endocrinol Metab"},{"key":"9710_CR99","first-page":"1823","volume":"56","author":"L Buscail","year":"1996","unstructured":"Buscail L, Saint-Laurent N, Chastre E, et al. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res. 1996;56:1823\u20137.","journal-title":"Cancer Res"},{"key":"9710_CR100","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/CPAA.S278978","volume":"13","author":"A Rouland","year":"2021","unstructured":"Rouland A, Bouillet B, Legris P, et al. Successful control of hypoglycemia with pasireotide LAR in a patient with inappropriate insulin secretion. Clin Pharmacol. 2021;13:33\u20137. https:\/\/doi.org\/10.2147\/CPAA.S278978.","journal-title":"Clin Pharmacol"},{"key":"9710_CR101","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s11695-019-04248-x","volume":"30","author":"CC \u00d8hrstr\u00f8m","year":"2020","unstructured":"\u00d8hrstr\u00f8m CC, Hansen DL, Kielgast UL, et al. A low dose of pasireotide prevents hypoglycemia in Roux-en-Y gastric bypass-operated individuals. Obes Surg. 2020;30:1605\u201310. https:\/\/doi.org\/10.1007\/s11695-019-04248-x.","journal-title":"Obes Surg"},{"key":"9710_CR102","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s00592-021-01723-9","volume":"58","author":"SU Muthunayake","year":"2021","unstructured":"Muthunayake SU, Feldt-Rasmussen U, Ringholm L. Off-label treatment with pasireotide and use of continuous glucose monitoring in late familial hyperinsulinemic hypoglycemia: a case report. Acta Diabetol. 2021;58:1123\u20135. https:\/\/doi.org\/10.1007\/s00592-021-01723-9.","journal-title":"Acta Diabetol"},{"key":"9710_CR103","doi-asserted-by":"publisher","DOI":"10.6065\/apem.2142010.005","author":"CF Mooij","year":"2021","unstructured":"Mooij CF, Tacke CE, van Albada ME, et al. First report on the use of pasireotide in a case of severe congenital hyperinsulinism due to a homozygous ABCC8 mutation. Ann Pediatr Endocrinol Metab. 2021. https:\/\/doi.org\/10.6065\/apem.2142010.005.","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"9710_CR104","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1177\/0003134820947371","volume":"86","author":"EC Dalton","year":"2020","unstructured":"Dalton EC, Johns MS, Rhodes L, et al. Meta-analysis on the effect of pasireotide for prevention of postoperative pancreatic fistula. Am Surg. 2020;86:1728\u201335. https:\/\/doi.org\/10.1177\/0003134820947371.","journal-title":"Am Surg"},{"key":"9710_CR105","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40842-020-00110-7","volume":"6","author":"X He","year":"2020","unstructured":"He X, Spencer-Segal JL. Rapid response of Nelson\u2019s syndrome to pasireotide in radiotherapy-naive patient. Clin Diabetes Endocrinol. 2020;6:22. https:\/\/doi.org\/10.1186\/s40842-020-00110-7.","journal-title":"Clin Diabetes Endocrinol"},{"key":"9710_CR106","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ando.2018.07.013","volume":"80","author":"H Lasolle","year":"2019","unstructured":"Lasolle H, Vasiljevic A, Borson-Chazot F, et al. Pasireotide: a potential therapeutic alternative for resistant prolactinoma. Ann Endocrinol (Paris). 2019;80:84\u20138. https:\/\/doi.org\/10.1016\/j.ando.2018.07.013.","journal-title":"Ann Endocrinol (Paris)"},{"key":"9710_CR107","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.2215\/CJN.13661119","volume":"15","author":"MC Hogan","year":"2020","unstructured":"Hogan MC, Chamberlin JA, Vaughan LE, et al. Pansomatostatin agonist pasireotide long-acting release for patients with autosomal dominant polycystic kidney or liver disease with severe liver involvement: a randomized clinical trial. Clin J Am Soc Nephrol. 2020;15:1267\u201378. https:\/\/doi.org\/10.2215\/CJN.13661119.","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-022-09710-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-022-09710-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-022-09710-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T02:26:57Z","timestamp":1653964017000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-022-09710-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":107,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["9710"],"URL":"https:\/\/doi.org\/10.1007\/s11154-022-09710-3","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,24]]},"assertion":[{"value":"6 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MB received lecture honoraria from Bausch, Ipsen, Novartis, Pfizer, Recordati, Teva. MK received lecture honoraria from HRA Pharma, Novartis, Recordati, Sanofi-Aventis. PW received lecture honoraria from Ipsen, Lilly, Novartis, Novo Nordisk, Recordati. AJP received lecture honoraria from Ipsen, Novartis, Pfizer, Recordati, Teva.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests\/Competing interests"}}]}}